Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yep last few weeks;I remember 2008/9 Pxs was 14 pence xx
Hope you mean over the last few weeks and not the past 5 years :o
Hopefully Pxs can have the same SP trajectory with good news as Optibiotix is having
The gut microbiota-derived metabolite trimethylamine-N-oxide (TMAO) is significantly associated with the risk of stroke, according to a study.
Specifically, higher TMAO levels resulted in a higher stroke risk, and stroke patients present with higher mean TMAO concentrations. High TMAO plasma levels also independently predict major adverse cardiovascular events (MACEs) and all-cause mortality.
In this systematic review and meta-analysis, the investigators searched the databases of PubMed, Embase, Cochrane Library, and Web of Science from 1 January 2001 to 1 June 2021.
https://specialty.mims.com/topic/trimethylamine-n-oxide-levels-linked-to-stroke-risk#
I buy another product from Healthspan, and I find them intensely irritating. My inbox, and my postbox, are swamped with junk from them. They've never promoted circulease, it isn't included in their heart health offerings. I don't believe they ever sold very much.
I am vegetarian. They do not have the vegetarian option.
Gix
Surely by now the transition issues have settled down re paperwork/supply chain so there really is NO reason for Healthspan to run out - after all they were third (?) after Sirco and Swansons to take up FF and have repeat orders to fill to the likes of DP.
Is IF prioritizing FF to new, non DSM, customers ? as we get more per serving with them. Are we seeing a ruthless side of him ?
W--anyone's-guess-as-exactly-what-IF-is-up-to--At-least-no-dilution-or-bailing-by-DSM-$
Absolutely. If all UK sales were direct from Provexis, we'd see a big addition to gross profits.
And cheaper. Also give PXS more profit
Why don't you order direct from PXS? :Delivered on time each month
Not sure why you automatically think that Healthspan being out of stock on one of their products is IF's problem.
Could be plenty of reasons why circulease is out of stock other than FF related.
I also did not receive my monthly packet. So what is happening now? Hope of our very good friend IF is doing something so that it will not out of stock for a long time.
Https://www.healthspan.co.uk/circulease-with-150mg-of-fruitflow/#
out of stock
No
I wonder if HMOs have ff in them ! The research study is at the bottom of this page . https://www.dsm.com/human-nutrition/en/products/hmos/hmos-for-gut-health.html
Doesn’t look like SL or DSM have reduced their holding ! Updated 21st July ....https://www.provexis.com/shareholder-information/major-shareholders/
To be fair the brochure doesn't mention any of their gut health ingredients by name.
Maybe it’s part of this . ..https://www.dsm.com/corporate/searchresults.html?query=Fruitflow+microbiota&pageNum=1&languageCode=en&siteName=corporate&filtersRequired=pageKeyWords
Health From The Gut doesn’t seem to include FF.
https://www.dsm.com/content/dam/dsm/human-nutrition/pdfs/aw-100897-dsm-hfg-brochure.pdf
When are we going to see this above 1p 🎻😁😁😭
"when are we going to learn more?"
If not before then by the end of September.
And this part:
The outsourced manufacturer of Fruitflow II SD (Fruitflow in spray dried powder form, the primary form of Fruitflow which is sold) is currently running some long-term stability tests on the product, with a possible view to an extension to the product's existing approved shelf life, and the results of these tests are expected in the coming weeks.
Since this statement................when are we going to learn more? Surely it's imperative we are updated on sales/cash position, when they advised it was so critical
The Company will be in a better position to judge how best to manage its future inventory requirements (which can be met from either: (i) DSM's existing Fruitflow inventory; or (ii) a new Fruitflow production run) in the coming weeks once it has a clearer picture of: (i) the likely demand from the Company's actual and prospective Fruitflow customers for the next 12 months and beyond, to include By-Health; and (ii) the outcome of the stability tests on the existing Fruitflow inventory. The Company is therefore currently seeking to negotiate an extension to the initial three month inventory handover period with DSM. While these negotiations progress the Company will receive incoming funds from further sales of the Company's existing Fruitflow inventory.
The Company remains in negotiations with a third party which might be able to hold inventory for the Company on a consignment basis, with the Company potentially only paying for the inventory when it is required for sale.
Based on the Company's current level of cash it continues to be expected that the Group will need to raise further equity finance, or potentially new loan finance, in the coming months. Considering the success of previous fundraisings and the current performance of the business, the Directors continue to have a reasonable expectation of raising sufficient additional equity capital or new loan finance.